SHANGHAI – The CFDA recently released "Guiding Principles for the Research and Evaluation of Cell Therapy Products" for trial implementation. This hotly anticipated move now adds cell therapies such as stem cells and chimeric antigen receptor (CAR T) therapies under the umbrella of CFDA reforms that are aligning China's drug regulations with global drug markets.